T Cells Induced by Vaccination and Following SIV Challenge Support Env-Specific Humoral Immunity in the Rectal-Genital Tract and Circulation of Female Rhesus Macaques
Overview
Authors
Affiliations
T follicular helper (T) cells are pivotal in lymph node (LN) germinal center (GC) B cell affinity maturation. Circulating CXCR5 CD4 T (cT) cells have supported memory B cell activation and broadly neutralizing antibodies in HIV controllers. We investigated the contribution of LN SIV-specific T and cT cells to Env-specific humoral immunity in female rhesus macaques following a mucosal Ad5hr-SIV recombinant priming and SIV gp120 intramuscular boosting vaccine regimen and following SIV vaginal challenge. T and B cells were characterized by flow cytometry. B cell help was evaluated in T-B cell co-cultures and by real-time PCR. Vaccination induced Env-specific T and Env-specific memory (ESM) B cells in LNs. LN Env-specific T cells post-priming and GC ESM B cells post-boosting correlated with rectal Env-specific IgA titers, and GC B cells at the same timepoints correlated with vaginal Env-specific IgG titers. Vaccination expanded cT cell responses, including CD25 Env-specific cT cells that correlated negatively with vaginal Env-specific IgG titers but positively with rectal Env-specific IgA titers. Although cT cells post-2 boost positively correlated with viral-loads following SIV challenge, cT cells of SIV-infected and protected macaques supported maturation of circulating B cells into plasma cells and IgA release in co-culture. Additionally, cT cells of naïve macaques promoted upregulation of genes associated with B cell proliferation, BCR engagement, plasma cell maturation, and antibody production, highlighting the role of cT cells in blood B cell maturation. Vaccine-induced LN T and GC B cells supported anti-viral mucosal immunity while cT cells provided B cell help in the periphery during immunization and after SIV challenge. Induction of T responses in blood and secondary lymphoid organs is likely desirable for protective efficacy of HIV vaccines.
Weaver K, Blackwood C, Horspool A, Pyles G, Sen-Kilic E, Grayson E Front Immunol. 2022; 13:838504.
PMID: 35211125 PMC: 8861382. DOI: 10.3389/fimmu.2022.838504.
Cheng X, Zhou L, Li Z, Shen S, Zhao Y, Liu C Front Immunol. 2022; 13:827865.
PMID: 35126400 PMC: 8811147. DOI: 10.3389/fimmu.2022.827865.